Today's Daily Dose brings you news about the new additions in the Russell 3000 Index; Citron's take on PolarityTE; Xeris Pharma's promising data from phase 3 clinical studies on liquid glucagon; Bio-Techne's acquisition; FDA approval of the first cannabis-based drug; Merrimack's disappointing CARRIE study results and a patient's death in Sophiris' prostate cancer study.
from RTT - Biotech https://ift.tt/2K7UCea
via IFTTT
No comments:
Post a Comment